How long does vascepa savings last?

Patent Exclusivity and Vascepa Savings

Vascepa, known generically as icosapent ethyl, is a medication used to treat high triglyceride levels. Its maker, Amarin Pharmaceuticals, held the patent for Vascepa in the United States until 2025 [1].

What does this mean for savings?

The 2025 patent expiration may have significant implications for Vascepa prices. Once the patent expires, generic versions of the medication may become available, which could lead to lower prices. However, the savings may not be immediate.

Generic Entrants and Savings Timeline

Generic drug manufacturers often begin the FDA approval process several years before a patent expires. If multiple generics are approved at the same time as the patent expiration, this could lead to a surge in competition and lower prices. However, it may take months or even years for the savings to be fully realized as pharmacies and retailers work to switch to the new generic versions [2].

Biosimilar and Generics Competition

While the patent expiration is a significant factor in determining the timeline for savings, it's essential to note that the availability of biosimilars and generics may affect the overall price of Vascepa. Biosimilars are highly similar versions of biologic medications like Vascepa, which could lead to increased competition and lower prices.

When does exclusivity expire?

Amarin's patent for Vascepa expires on April 30, 2025, according to the Orange Book, which is also available on DrugPatentWatch.com [3].

What to Expect in the Future

As the patent expires and generic versions become available, patients may experience savings on their medication. However, the timing and magnitude of these savings depend on various factors, including the entry of biosimilars and generics, as well as changes in market dynamics.

References:

[1] DrugPatentWatch.com (2023)
[2] FDA.gov (2023)
[3] DrugPatentWatch.com (2023)